The bulk of the currently available evidence of a potential anticancer activity of cannabis comes from preclinical models, ranging from cancer cell lines in culture to genetically engineered mice. Overall, these studies have reported that THC, as well as other cannabinoids (either natural or synthetic), can bind to and activate cannabinoid receptors (type 1 [CB1] and/or type 2 [CB2]) located on the surface of cancer cells, thereby modulating intracellular signaling pathways […]
Leer másThis document focuses on priority areas for medicinal cannabis-related research. The authors, an international group of cannabis experts, have compiled this list, based on their extensive cannabinoid research experience.
Leer másCannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana.
Leer másCannabis has long been known to limit or prevent nausea and vomiting, lack of appetite, and pain. For this reason, cannabinoids have been successfully used in the treatment of some of the unwanted side effects caused by cancer chemotherapy. Besides their palliative effects, research from the past two decades has demonstrated their promising potential as antitumor agents in a wide variety of tumors […]
Leer másAs oncologists are understandably most convinced by results published in the medical literature, this article will summarize currently available evidence.
Leer másSince 2010, Israeli patients with cancer can receive a permit for cannabis use for palliation after a recommendation by their treating oncologist. According to the Israeli Ministry of Health, more than 10 000 patients with cancer receive permits annually, making it the most commonly prescribed medication by the Israeli oncologists.
Leer másUntil recently, cannabis and its derivatives were widely restricted under legislation which stated they had no medical value and carried a substantial risk of misuse. Policy is rapidly changing, and cannabis can now be prescribed for medicinal use in many countries, including the UK.
Leer másEl efecto terapéutico de una variedad de cannabis viene determinado por el porcentaje de cannabinoides, terpenos, flavonoides y otras sustancias activas que encontramos en las diferentes variedades o cepas. Los terpenos modulan y complementan los efectos de los cannabinoides, además de proporcionarnos el sabor y olor de cada variedad, y son los responsables de la resistencia de la planta a los depredadores […]
Leer másEn este último decenio, y especialmente en los últimos 2 años, se ha incrementado de manera ostensible el interés y la demanda de información sobre el uso terapéutico del cannabis. Ya conocemos las 4 indicaciones clásicas del uso de cannabis, que comprenden el tratamiento del dolor, la atenuación de las náuseas y vómitos secundarios a un tratamiento de quimioterapia, el incremento del apetito, y el tratamiento de la espasticidad en enfermedades neurodegenerativas (especialmente esclerosis múltiple). Estas indicaciones están aceptadas por la comunidad científica, lo cual no quiere decir que los cannabinoides se utilicen o se planteen como una alternativa terapéutica normalizada. En este ámbito, es importante resaltar que carecemos a día de hoy de ensayos clínicos que nos demuestren y confirmen la efectividad de los cannabinoides en determinadas enfermedades […]
Leer másThis review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain […]
Leer másCannabis‐based medicines are being approved for pain management in an increasing number of European countries. There are uncertainties and controversies on the role and appropriate use of cannabis‐based medicines for the management of chronic pain. EFIC convened a European group of experts, drawn from a diverse range of basic science and relevant clinical disciplines, to prepare a position paper to empower and inform specialist and nonspecialist prescribers on appropriate use of cannabis‐based medicines for chronic pain.
Leer másDebemos partir de la base de que en la planta de cannabis hay una muy compleja mezcla de sustancias activas, que pueden presentarse en proporciones diferentes según la variedad, o no estar presentes en algunas preparaciones. Esta cuestión es crucial para entender que las cualidades terapéuticas de una variedad de cannabis dependen de muchos factores. Es primordial desde el punto de vista terapéutico conocer el porcentaje de cannabinoides de las variedades a utilizar, así como la ausencia de contaminantes como pesticidas, hongos, bacterias o metales pesados. Cuanta más información tengamos sobre los porcentajes de cannabinoides y a ser posible de terpenos de la variedad a utilizar, mejor podremos predecir los efectos que probablemente beneficiarán al paciente.
Leer másEl olor está implicado en el efecto de mejora del apetito de los cannabinoides. Los investigadores encontraron que los receptores CB1 mejoran la ingesta de alimentos en ratones en ayunas al aumentar la detección del olor…
Leer másLos médicos de la Escuela de Medicina de Harvard de Boston presentaron un caso de una mujer de 58 años con antecedentes de náuseas, vómitos, dolor abdominal e incapacidad de mantener la ingesta oral después de múltiples cirugías abdominales…
Leer másEn un estudio con musarañas (Suncus murinus) la activación del receptor CB2 redujo las náuseas y los vómitos…
Leer másWe performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles…
Leer másEl síndrome de Dravet puede estar asociado con una desregulación del sistema endocannabinoide…
Leer másEl síndrome de Dravet puede estar asociado con una desregulación del sistema endocannabinoide…
Leer másEstudios celulares sugieren que el cannabidiol (CBD) podría ejercer sus efectos anticonvulsivos, al menos en parte, a través de su acción sobre ciertos canales de la membrana celular (canales de sodio dependientes de voltaje) y la corriente emergente podría ser una diana terapéutica prometedora para el tratamiento de los síndromes epilépticos…
Leer másThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of Cannabis and cannabinoids in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH)…